Closing the Gaps: How ICL’s PLBL2 Outperforms USP's Analytical Reference Standard

Introduction

Host Cell Proteins (HCPs) remain one of the most persistent challenges in biopharmaceutical manufacturing. Among them, phospholipase B-like 2 (PLBL2) from CHO cells is notorious for co-purifying with monoclonal antibodies and triggering immunogenic responses. A recent study published by Michael Dolan and colleagues, published in Biotechnology and Bioengineering offers the most comprehensive characterization of PLBL2 to date, revealing its extraordinary complexity and significant implications for downstream processing.

This characterization underscores why PLBL2 has become a focal point for regulatory scrutiny and process optimization. Its structural complexity and tendency to resist clearance through conventional purification steps highlight the limitations of generic HCP assays, which often fail to detect such problematic species. As biopharmaceutical pipelines grow more diverse, the need for orthogonal and protein-specific strategies becomes critical, not only to ensure product safety but also to streamline comparability studies and accelerate timelines. Targeted tools, such as protein-specific ELISAs, can provide actionable insights into clearance efficiency and help mitigate immunogenicity risks before they escalate into regulatory hurdles.

Key Insights from the Study

The research team employed site-specific antibody immobilization and affinity enrichment to isolate PLBL2 from pembrolizumab, enabling deep structural analysis. Here’s what they found:

  • Charge Variants: Multiple isoforms spanning pI ~5.0–6.0
  • Size Variants: Isoforms at ~80 kDa, ~45 kDa, and ~30 kDa
  • Post-Translational Modifications: Five N-linked glycosylation sites (>98% occupancy) O-linked glycosylation at T3 Phosphorylation at H39, S85, T167, S468, H487

These findings underscore why PLBL2 resists clearance during standard purification steps and why precise detection and quantitation are critical for patient safety and regulatory compliance.

Why ICL’s PLBL2 Protein Should Be Your Gold Standard

ICL offers high-purity recombinant CHO PLBL2 and validated antibodies that enable accurate detection and quantitation of this challenging impurity. Here’s why our protein sets the benchmark:


Authentic Sequence & Structure: Matches endogenous CHO PLBL2, ensuring assay relevance

Extensive Validation: Supports ELISA development, LC-MS workflows, and orthogonal testing strategies

Consistency & Reliability: Manufactured under stringent quality controls for reproducible results

How ICL Outperforms USP’s Analytical Reference Material (ARM)

The recent study revealed critical gaps in the USP ARM for PLBL2. Here’s why ICL’s PLBL2 (Cat# AG65-0365) protein sets the benchmark:

  • Comprehensive Sequence Coverage: ICL achieves ~99% cumulative coverage (Figure 1), enabling robust LC-MS workflows.
  • Full PTM Profile: USP ARM reports only two N-linked sites and one cleavage site—missing O-linked glycosylation and phosphorylation entirely.
  • Accurate Cleavage Site: USP lists S202/C203; study confirms C203/S204, essential for structural modeling.
  • Expanded Glycosylation: ICL includes five N-linked sites (>98% occupancy) plus O-linked glycosylation at T3.
  • Phosphorylation Insights: ICL captures five phosphorylation sites (H39, S85, T167, S468, H487)—USP reports none.

Bottom line: When precision matters, start with a reference material that reflects the true complexity of PLBL2.

Why This Matters:  Accurate reference materials drive confidence in HCP detection and clearance strategies. Using a protein that mirrors endogenous PLBL2 complexity ensures your assays meet regulatory expectations and mitigate immunogenic risk.

When regulatory expectations demand confidence in your HCP analysis, starting with the right reference material is non-negotiable. ICL’s PLBL2 protein provides that confidence.

Want to learn more about how ICL can support your HCP strategy? Contact us today or explore our PLBL2 resources: https://www.icllab.com/host-cell-proteins.html

#Bioprocessing #HostCellProteins #CHOCells #QualityByDesign #ICL #BiopharmaAnalytics